VRTX Q2 2023 Earnings — Vertex Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

VRTXVertex Pharmaceuticals Incorporated

$129B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2.5B+13.5% YoY

Gross Profit

$2.2B87.6% margin

Operating Income

$1.0B41.2% margin

Net Income

$916M36.7% margin

EPS (Diluted)

$3.52

QoQ Revenue Growth

+5.0%

Cash Flow

Operating Cash Flow

$1.1B

Free Cash Flow

$1.1B

Stock-Based Comp.

$119M

Balance Sheet

Total Assets

$20.3B

Total Liabilities

$4.9B

Stockholders' Equity

$15.5B

Cash & Equivalents

$10.2B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.5B	$2.2B	+13.5%
Gross Profit	$2.2B	$1.9B	+12.9%
Operating Income	$1.0B	$1.1B	-7.2%
Net Income	$916M	$811M	+13.0%

Revenue Segments

TRIKAFTA/KAFTRIO

$2.2B90%

KALYDECO

$125M5%

ORKAMBI

$96M4%

SYMDEKO/SYMKEVI

$31M1%

Geographic Segments

UNITED STATES

$1.5B60%

Europe

$800M32%

Other, Non U.S.

$185M7%